- IDEXX Laboratories stock steadies after Q2 2026 beat and fresh guidance
Ad-hoc-news.de · Aug 29, 2026
- Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?
Yahoo Finance · Aug 26, 2026
Wall Street analysts have released new price targets and forecasts for IDEXX Laboratories stock. This evaluation provides investors with crucial insight into market expectations and the company's financial trajectory.
- IDEXX Laboratories stock holds below highs as investors weigh earnings momentum
Ad-hoc-news.de · Aug 26, 2026
- IDEXX Laboratories stock holds below highs as investors weigh earnings momentum
Ad-hoc-news.de · Aug 26, 2026
- IDEXX Laboratories stock holds above $540 as investors eye recurring diagnostics growth
Ad-hoc-news.de · Aug 22, 2026
- IDEXX Laboratories stock holds above $540 as investors eye recurring diagnostics growth
Ad-hoc-news.de · Aug 22, 2026
- IDEXX Laboratories stock holds high valuation as earnings outlook firms
Ad-hoc-news.de · Aug 21, 2026
- IDEXX Laboratories stock holds high valuation as earnings outlook firms
Ad-hoc-news.de · Aug 21, 2026
- IDEXX launches first dual-species point-of-care NT-proBNP test for cardiac disease in cats and dogs | dvm360
dvm360 · Aug 20, 2026
IDEXX Laboratories expanded its Catalyst diagnostic platform with a new dual-species point-of-care NT-proBNP test to evaluate cardiac disease in cats and dogs. The assay integrates directly with VetConnect PLUS to provide veterinarians with real-time biomarker insights during clinical examinations.
- IDEXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
Zacks Investment Research · Aug 20, 2026
Following a strong second-quarter earnings beat driven by 10% organic growth in recurring veterinary diagnostics, IDEXX raised its full-year earnings per share guidance. The results highlight strong testing utilization and margin expansion despite softer U.S. clinic visit trends.
- IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
Zacks Investment Research · Aug 20, 2026
IDEXX Laboratories raised its full-year 2026 earnings guidance following a robust second-quarter earnings report. Strong recurring veterinary diagnostics sales and wider operational margins helped offset softer U.S. veterinary clinical visit volumes.
- Resilient IDEXX Laboratories stock trades in the mid-$550s as investors weigh premium valuation and
AD HOC NEWS · Aug 19, 2026
- Resilient IDEXX Laboratories stock trades in the mid-$550s as investors weigh premium valuation and
Ad-hoc-news.de · Aug 19, 2026
- IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
All Articles on Seeking Alpha · Aug 18, 2026
IDEXX Laboratories hosted its annual analyst and investor day to discuss long-term strategic growth and financial targets. This event provides investors with key visibility into the company's future operational goals and technology roadmap.
- IDEXX Laboratories stock holds above the mid-$540s as valuation stays demanding
AD HOC NEWS · Aug 18, 2026
- IDEXX Laboratories stock holds above the mid-$540s as valuation stays demanding
Ad-hoc-news.de · Aug 18, 2026
- IDEXX Labs Executing, But Valuation Continues To Weigh On That Execution (NASDAQ:IDXX)
Seeking Alpha · Aug 18, 2026
- IDEXX Labs Executing, But Valuation Continues To Weigh On That Execution (NASDAQ:IDXX)
Seeking Alpha · Aug 18, 2026
- IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
All Articles on Seeking Alpha · Aug 14, 2026
IDEXX Laboratories hosted its investor day, presenting strategic updates and financial outlooks to stakeholders. This event provides investors with critical insights into the company's long-term growth drivers and market positioning.
- IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
Seeking Alpha · Aug 14, 2026
IDEXX Laboratories hosted its 2026 Investor Day presentation at its corporate headquarters, detailing strategic updates on its veterinary diagnostics business and long-term growth vectors.